Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuqing Lou

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
Clinical and Translational Medicine|May 31, 2023
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapyTianqing Chu, Jie Yuan, Jun Lu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 9, 2019
Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung CancerJun Lu, Hua Zhong, Jun Wu, et al.
Signal Transduction and Targeted Therapy|September 11, 2025
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancerJun Lu, Minjuan Hu, Yikai Zhao, et al.
Translational Lung Cancer Research|August 12, 2022
Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective studyTianqing Chu, Wei Zhang, Bo Zhang, et al.
Plos Genetics|April 20, 2016
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung CancerLiyan Jiang, Jiaqi Huang, Brandon W Higgs, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
Clinical and Translational Medicine|May 31, 2023
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapyTianqing Chu, Jie Yuan, Jun Lu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 9, 2019
Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung CancerJun Lu, Hua Zhong, Jun Wu, et al.
Signal Transduction and Targeted Therapy|September 11, 2025
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancerJun Lu, Minjuan Hu, Yikai Zhao, et al.
Translational Lung Cancer Research|August 12, 2022
Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective studyTianqing Chu, Wei Zhang, Bo Zhang, et al.
Plos Genetics|April 20, 2016
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung CancerLiyan Jiang, Jiaqi Huang, Brandon W Higgs, et al.
Pageof 12